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ABSTRACT 
Objective – To evaluate whether cardiorespiratory fitness (CRF) and heart rate recovery (HRR) 
associate with the risk of sudden cardiac death (SCD) independently of left ventricular ejection 
fraction (LVEF). 
 
Methods – The Finnish Cardiovascular Study (FINCAVAS) is a prospective clinical study of 
patients referred to clinical exercise testing in 2001-2008 and follow-up until December 2013. 
Patients without pacemakers undergoing first maximal or submaximal exercise testing with cycle 
ergometer were included (n=3776). CRF in metabolic equivalents (METs) was estimated by 
achieved maximal work level. HRR was defined as the reduction in heart rate one minute after 
maximal exertion. Adjudication of SCD was based on death certificates. LVEF was measured for 
clinical indications in 71.4% of the patients (n=2697). 
 
Results – Population mean age was 55.7 years (SD 13.1)(61% men). 98 SCDs were recorded 
during a median follow-up of 9.1 years (6.9–10.7). Mean CRF and HRR were 7.7(SD 2.9) METs 
and 25(SD 12) beats/min/min. Both CRF and HRR associated with the risk of SCD in the entire 
study population (HRCRF 0.47[0.37-0.59], p<0.001 and HRHRR 0.57[0.48-0.67], p<0.001 with HR-
estimates corresponding to one SD increase in the exposure variables) and with CRF, HRR and 
LVEF in the same model (HRCRF 0.60[0.45-0.79], p<0.001, HRHRR 0.65[0.51-0.82], p<0.001) or 
adjusting additionally for all significant risk factors for SCD (LVEF, sex, creatinine level, history of 
myocardial infarction and atrial fibrillation, corrected QT interval) (HRCRF 0.69 [0.52-0.93], 
p<0.01, HRHRR 0.74 [0.58-0.95], p=0.02). 
 
Conclusions – CRF and HRR are significantly associated with the risk of SCD regardless of LVEF.
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What is already known about this subject? 
Cardiorespiratory fitness and heart rate reduction measured in clinical exercise testing have been 
associated with the risk of sudden cardiac death among populations undergoing clinical exercise. 
Earlier studies have been performed largely before the era of measuring left ventricular ejection 
fraction routinely in clinical work and before the use of most medical therapies aimed to reduce the 
risk of sudden cardiac death.  
 
 
What does this study add? 
The novel observations of the present contemporary study population demonstrate that the 
associations between cardiorespiratory fitness and heart rate reduction and sudden cardiac death are 
independent of left ventricular ejection fraction, which is currently the cornerstone in evaluating the 
risk of sudden cardiac death.  
 
How might this impact on clinical practice? 
The risk of sudden cardiac death can be evaluated by measuring cardiorespiratory fitness and heart 
rated reduction during clinical exercise testing despite the fact that left ventricular ejection fraction 
is known. They can also be used to evaluate the risk of sudden cardiac death among patients with 
only slightly reduced or normal ejection fraction. 
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INTRODUCTION 
 
The vast majority of all sudden cardiac deaths (SCDs) occur among individuals with no apparent 
heart disease or with only slightly reduced left ventricular ejection fraction (LVEF). Currently only 
patients with a reduced left ventricular ejection fraction (LVEF <35%) or with very rare conditions 
are eligible for an implantable cardioverter-defibrillator (ICD) for primary prevention of SCD given 
their high risk for the event [1–3]. 
Clinical exercise testing can be used to assess probability of coronary artery disease 
(CAD) and to improve prognostic evaluation [4–12]. It provides an easy way to quantify 
cardiorespiratory fitness (CRF) in metabolic equivalents (METs) indirectly by measuring achieved 
work level. Only few previous studies that have linked CRF with the risk of SCD[4,13,14]. In 
addition to CRF, heart rate recovery (HRR), which is very simple to assess as the difference in heart 
rate from the peak exercise to one minute post-exercise, has also been linked with SCD among men 
[4].  
Currently there is no evidence of the prognostic value of exercise testing for SCD, if 
left ventricular ejection fraction (LVEF), which is the most significant risk factor for SCD, is 
included as a prognostic factor. Furthermore, previous studies [4,13,14] have been performed 
before the era of wide spread use of statins, angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARBs) in the medical management of CAD and heart failure and 
the use of ICDs in primary prevention of SCD [3].  
The purpose of this study was to evaluate the clinical utility of CRF and HRR, both 
associated with the function of cardiac autonomic nervous system [15,16], in predicting SCD 
regardless of LVEF and in a contemporary setting. For this purpose, we used data from a 
prospective The Finnish Cardiovascular Study (FINCAVAS) of 3776 patients undergoing clinical 
exercise testing between 2001 and 2008 with almost a decade of follow-up.
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MATERIAL AND METHODS 
  
Study population 
The patient population of FINCAVAS comprises all willing consecutive patients between October 
2001 and December 2008 who were referred for an exercise test at Tampere University Hospital. 
Some patients performed multiple exercise tests but only the first technically successful exercise 
test for each patient was included into the study (n=4068). A technically successful exercise test 
was defined as a test with reliably measured heart rate, blood pressure and ECG. Only patients 
without pacemakers or ICDs performing the exercise test on a cycle ergometer and reaching 
maximal or almost maximal level of exercise were included (n=3776). Indications for the exercise 
are presented in supplementary material. The Ethics Committee of Tampere University Hospital 
District approved the study protocol, and all patients gave written informed consent. This study 
adheres to the Declaration of Helsinki. Details of the study have been published earlier in more 
detail [17]. 
 
Patient and public involvement 
Patients were not involved in the study design or interpretation or dissemination of the results. 
 
Study protocol 
Relevant medical history was documented before the exercise. Resting ECG was recorded using 
Mason-Likar 12-lead prior to exercise after 10 minutes in supine position. All patients aimed to 
reach maximal heart rate, except patients who were evaluated soon after MI (7.6%) where an upper 
heart rate limit of 120-130 beats/min was applied. The initial workload was 20 to 30 W. The 
workload was increased stepwise by 10–30W every minute based on individual patient 
characteristics. ECGs were digitally recorded at 500 Hz with the CardioSoft exercise system 
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(Version 4.14, GE Healthcare, Freiburg, Germany). Blood pressure was measured manually with a 
brachial cuff before the test, during exercise and in the recovery phase. After termination of the test, 
the subjects remained at the cycle ergometer seated for at least four minutes and paddled slowly 
against 10W resistance for a minute to allow for safe hemodynamic recovery.  
 
Measuring CRF and HRR 
CRF or exercise capacity in METs was estimated by achieved workload in reference to patients 
body weight using a standard formula of the GE Cardiosoft Software: METs =  (12×Workload + 
3.5×bodyweight) / 3.5×bodyweight, with 1 MET corresponding to an estimated 3.5 ml oxygen 
uptake/kg/min. HRR was defined as the difference between maximum heart rate during exercise 
and heart rate after the first minute following cessation of exercise.  
 
Measurement of LVEF 
LVEF information was available in n=2697 (71.4%) study patients. LVEF values were measured 
for clinical indications by echocardiography, invasive contrast left ventriculography or by gated 
myocardial perfusion scintigraphy and the information was extracted retrospectively from patient 
records. If the patients had multiple measurements, the most recent measurement before the 
exercise test was preferred. Median time between the exercise test and LVEF measurement was 8 
weeks (interquartile range [IQR] 3-56 weeks). LVEF measured after the exercise test was used only 
if it preceded death by at least one year and there were no measurements before the test was 
available. 
 
Follow-up and end-points 
The primary endpoint of this study was SCD. For the definition of SCD, death certificates listing 
the circumstances of the deaths and specific causes of death (based on the 10th revision of the 
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International Classification of Diseases) were received from the Causes of Death Register 
maintained by Statistics Finland. The autopsy rate was 46% for all deaths. The adjudication 
committee for the definition of cause of death comprised three physicians who all reviewed the 
death certificates blinded to the exercise test results. SCD was defined as sudden and unexpected 
death by a primary cardiac cause (without any evidence or other probable cause) and occurring 
within approximately one hour from the onset of symptoms or if the death was not witnessed if the 
person had last been seen symptomless within 24 hours of the death. In 84% of the SCDs (82/98), 
the foremost contributing cause of death was CAD. Loss to follow-up for the main end-point data 
was 0%. 
In order to capture all possible occurrences of potentially fatal arrhythmias during the 
follow-up, we also formed a secondary end-point named as cardiac arrest (CA) by combining all 
aborted cardiac arrests with SCDs. Cardiac arrests were first screened by searching for ICD-10 
based diagnoses of resuscitations and ventricular fibrillation from the hospital districts discharge 
diagnose database. Ventricular tachycardia without resuscitation was not considered as a cardiac 
arrest. Implantation of ICD devices were monitored also from hospital electronic health registry. 
  
Statistical analysis  
Main exposure variables were CRF and HRR. The prognostic significance of main exposure 
variables was primarily tested with a linear Cox cause-specific hazard model with other causes of 
death during the follow-up censored (i.e. coded as negative cases) and with time-on-study as time 
scale. CRF, HRR and LVEF were standardized and centered to mean (value ±1 depicting one 
standard deviation [SD] change from zero and value 0 depicting population mean) to facilitate 
interpretation of the results. For this reason, all hazard ratio (HR) estimates presented correspond to 
the change in risk related to one SD change in the exposure variable. The main exposure variables 
and covariates fulfilled the proportionality assumption based on correlations on survival rankings 
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with Schoenfeld residuals. All factors depicting comorbidities and patient characteristics associating 
significantly with SCD in univariate models were considered in the multivariable analysis. 
Significant risk factors were selected to the final multivariable model by a backward elimination 
algorithm (stepwise probability for entry 0.05 and probability of removal 0.1) considering 
preliminary all risk factor associating significantly with the risk of SCD in univariate analyses. The 
linearity of the associations for continuous main exposure variables were assessed by Cox 
regression modeling with penalized splines. Missing values for continuous variables missing less 
than 5% of values were replaced by multiple imputation by chained equations (missing data for 
HRR n=138 [3.7%], serum creatinine n=128 [3.4%], blood pressure values n=5 [0.01%], QT and 
QTc interval n=173 [4.6%], QRS interval n=121 [3.2%]) but the main analyses were also repeated 
without using any imputed data and presented in the online supplement. All statistical tests were 
two-tailed and used an alpha level of 0.05. Statistical analyses were performed with the R studio 
version 1.1383(R Foundation for Statistical Computing, Vienna, Austria) (packages: ‘mice’, 
‘ggplot2’, ‘survival’, ‘psplines’).  
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RESULTS 
 
Characteristic of the study population 
Median follow-up time of the study was 9.1 years (IQR 6.9-10.7). During the follow-up 534 
patients died (14.1%) with 98 deaths classifiable as SCDs (18.4%) and 436 deaths due to other 
causes (81.6%). The differences in baseline demographics between patients who suffered a SCD, 
patients died of other causes and patients live at the end of the follow-up are presented in 
Supplementary Table 1. Additionally, during the follow-up 47 patients suffered aborted cardiac 
arrest and were successfully resuscitated. Seven of these patients ultimately died of SCD totaling 
overall 138 CAs during the follow-up period. Two percent (n=75) of the population received an 
ICD device during the follow-up. Only two of these patients suffered SCD. 
Information of LVEF was available in 71.4% of the cases (n=2696). As expected, 
these patients were older and with more comorbidities when compared to patients with no clinical 
indication for LVEF measurement (Table 1.). The distributions of CRF and HRR in the study 
population are presented in Figure 1.
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Table 1. Population characteristics of 3776 patients of the FINCAVAS Study  
 ALL 
N=3776 
100% 
LVEF Sig.* 
Not measured 
28.6% 
Measured 
71.4% 
Age 55.7 (13.1) 55.8 (11.6) 55.7 (13.6) 0.844 
Body-Mass Index 27.5 (4.6) 27.9 (4.8) 27.3 (4.5) 0.002 
Men 60.6% (2264) 48.7% 65.3% <0.001 
Smoker 22.2% (837) 20.7% 22.8% 0.161 
Previous Myocardial Infarction 26.4% (993) 15.4% 30.7% <0.001 
Previous Stroke 5.8% (219) 4.9% 6.2% 0.120 
Diabetes 14.4% (542) 13.0% 14.9% 0.128 
Cancer (any) 10.5% (396) 10.9% 10.4% 0.655 
Heart Failure 6.3% (237) 2.6% 7.8% <0.001 
Pulmonary Disease† 10.7% (402) 11.5% 10.3% 0.287 
Peripheral Artery Disease 2.9% (108) 2.9% 2.7% 0.728 
Atrial Fibrillation 16.4% (618) 9.2% 19.2% <0.001 
Dementia  0.9% (33) 0.9% 0.9% 0.847 
Use of Medications:     
ACEI/ARB 34.9% (1317) 30.1% 36.8% <0.001 
Beta blockers 54.9% (2071) 38.4% 61.5% <0.001 
Diuretics 20.1% (824) 18.5% 19.7% 0.433 
Digoxin 3.2% (131) 1.3% 3.7% <0.001 
Lipid Lowering Agent‡ 38.9% (1463) 28.4% 43.1% <0.001 
Serum Creatinine, umol/L 86.4 (73.7) 79.3 (40.2) 89.1 (83) <0.001 
Cardiorespiratory fitness (MET) 7.7 (2.9) 7.9 (2.8) 7.7 (3.0) 0.054 
Heart Rate Recovery (bpm/min) 24.8 (11.6) 25.0 (10.0) 24.7 (12.2) 0.376 
Max. Heart Rate (bpm) 147 (27) 152 (24) 144 (28) <0.001 
Max. Blood Pressure (mmHg) 195 (29) 201 (27) 193 (29) <0.001 
Sig. ST-depression§ 48.7% (1839) 43.5% 52.0% <0.001 
SCD during follow-up 2.6% (98) 2.1% 2.8% 0.257 
Death during follow-up 14.1% (534) 11.6% 15.2% 0.004 
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*For the comparison of patients with or without measured left ventricular ejection fraction, † 
(COPD or Asthma), ‡99% statin users. §A ST segment depression of 0.1mV or more during the 
maximal exertion or in recovery phase. Abbreviations: Sig; Significance, SCD, Sudden Cardiac 
Death; ACEI, Angiotensin-converting enzyme Inhibitor; ARB, Angiotensin II Receptor Blocker; 
LVEF, Left Ventricular Ejection Fraction; METs, Metabolic Equivalents; bpm, Beats per minute 
 
 
The association between CRF, HRR and SCD 
Before adjusting for any other risk factors both CRF and HRR associated with the risk of SCD in 
the entire study population (univariate analysis: HRCRF 0.47, 95% CI 0.37-0.59, p=1.7e
-10 and 
HRHRR 0.57, 95% CI 0.48-0.67, p=2.5e
-11). After adjusting for LVEF, both variables still remained 
significantly associated with SCD (HRCRF 0.52, 95% CI 0.39-0.68, p=3.4e
-6 and HRHRR 0.60, 95% 
CI 0.49-0.73, p=3.3e-7). When all three factors (CRF, HRR and LVEF) were included in the same 
model, all associations were significant (HRCRF 0.60, 95% CI 0.45-0.79, p=2.2e
-4, HRHRR 0.65, 95% 
CI 0.51-0.82, p=2.9e-4 and HRLVEF 0.67, 95% CI 0.54-0.83, p=2.5e
-4). The results remained similar 
when analysis was restricted to only patients with recent LVEF measurement (within three months, 
n=1451)(LVEF adjusted: HRCRF 0.55, 95% CI 0.37-0.81, p=0.003 and HRHRR 0.57, 95% CI 0.39-
0.82, p=0.002) or restricting the analyses to subjects with no imputed data (Supplementary Table 2) 
Results of more extensive multivariable models are presented in Table 2., with 
additional adjustments made for all significant risk factors associating with SCD in the entire study 
population (including markers of electrophysiological instability such as QRS duration or corrected 
QT interval). Further adjustment for prescribed medications, did not change the results significantly 
despite the fact that they too are associated with CRF and HRR (Supplementary Table 3). The 
development of the SCD risk related to CRF and HRR in the entire study population is 
demonstrated in Figure 2., showing a tendency for non-linear association. The trends were similar 
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after adjusting for LVEF (Supplementary Figure 1). The associations between main exposure 
variables and other risk factors with the risk of dying to any other cause are presented in 
Supplementary Table 4 and the combined effects of CRF and HRR on the risk of SCD are 
presented in Supplementary Table 5.  
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Table 2.  The association between baseline risk factors (comorbidities and patient 
characteristics) and sudden cardiac death in the FINCAVAS study population (n=3776). 
Information of left ventricular ejection fraction (LVEF) was available in 71.4% (n=2697) of 
the study population.  
 Hazard ratio (95% Confidence Interval)* 
 Univariate Multivariable Multivariable with LVEF 
Age 1.03 (1.01-1.05) - - 
Body-Mass Index 1.08 (1.04-1.12) - - 
Sex (Male) 2.90 (1.74-4.83) 2.09 (1.23-3.55) 2.09 (1.11-3.95) 
Smoking 1.26 (0.81-1.96) - - 
Previous MI 5.09 (3.36-7.69) 3.72 (2.41-5.73)  3.80 (2.28-6.34) 
Previous Stroke 1.95 (1.01-3.75) - - 
Diabetes 2.61 (1.69-4.03) - - 
Cancer (any) 1.59 (0.89-2.85) - - 
Heart Failure 4.32 (2.61-7.13) - - 
Pulmonary Disease† 2.20 (1.34-3.59) 1.80 (1.09-2.96) 1.76 (0.99-3.13) 
Peripheral Artery Disease 3.58 (1.73-7.37)  - 
Atrial Fibrillation 2.48 (1.62-3.80) 1.93 (1.23-3.02) 1.86 (1.15-3.18) 
Dementia due to any cause 1.28 (0.18-9.17) - - 
Serum Creatinine 1.15 (1.06-1.25) 1.14 (1.03-1.27) 1.12 (1.01-1.25) 
Cardiorespiratory fitness  0.47 (0.37-0.59) 0.63 (0.48-0.81) 0.69 (0.52-0.93) 
Heart Rate Recovery  0.57 (0.49-0.68) 0.74 (0.60-0.92) 0.74 (0.58-0.95) 
Max. Heart Rate 0.57 (0.49-0.68) - - 
Max. Blood Pressure  0.61 (0.50-0.75) - - 
Sig. ST-depression‡ 0.60 (0.40-0.91) - - 
QTc-interval 1.37 (1.15-1.65) - 1.25 (1.01-1.51) 
QRS duration 1.37 (1.21-1.57) 1.25 (1.07-1.45) - 
LVEF 0.61 (0.49-0.76) NA - 
LVEF ≤35%§ 6.41 (3.58-11.48) NA 3.35 (1.84-6.10) 
 14 
*Hazard ratio estimates correspond to a one standard deviation increase in exposure variables for 
continuous risk factors except for age for which the hazard estimate corresponds to a one-year 
increase. Risk estimates for multivariable analyses are reported only for variables associating with 
SCD with a p-value of <0.05 in the final model. Significant risk factors were selected to the model 
by a backward elimination algorithm. †Chronic Obstructive Pulmonary Disease or Asthma. ‡At 
least 0.1mV ST-segment depression during or after the exercise. §Multivariable model without 
LVEF as continuous variable in the model 
 
 
Interactions and sensitivity analyses  
The unadjusted associations between main exposure variables and SCD were all consistent and 
significant among different patient subpopulations stratified by the use of medications and with 
different indications for the exercise test (Table 3) and among patients with LVEF >35%. 
Interestingly, interaction analyses revealed that poor HRR might be a stronger risk factor among 
women when compared to men (p=0.01 for interaction) and also when HRR was measured from an 
almost maximal exercise test when compared to maximal exercise test (p=0.02 for 
interaction)(Table 3).  
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Table 3. The unadjusted association between exercise test parameters and sudden cardiac 
death among different subgroups of patients undergoing clinical exercise testing. Results 
presented in bold text have nominally significant (p<0.05) interaction suggesting significantly 
different hazard ratios between subgroups. 
 Hazard Ratios (95% Confidence Interval) 
 Cardiorespiratory Fitness Heart Rate Recovery 
All, n=3776 0.47 (0.37-0.59) 0.57 (0.49-0.68) 
Sex   
Men, n=2262 0.43 (0.33-0.55) 0.65 (0.55-0.79) 
Women, n=1470 0.46 (0.25-0.84) 0.32 (0.19-0.55) 
LVEF function   
LVEF >35%, n=2584** 0.55 (0.41-0.73) 0.62 (0.51-0.75) 
LVEF <35%, n=113 0.34 (0.15-0.81) 0.76 (0.40-1.44) 
Users of different medications:   
Beta-blockers, n=2071 0.42 (0.31-0.57) 0.55 (0.44-0.70) 
ACEI or ARB, n=1317 0.51 (0.37-0.70) 0.55 (0.42-0.74) 
Lipid lowering agent*, n=1463 0.52 (0.36-0.75) 0.58 (0.43-0.77) 
Patients with different indications:   
Suspicion of CAD, n=1603 0.52 (0.33-0.79) 0.42 (0.27-0.63) 
Evaluation of drug therapy, n=459 0.53 (0.31-0.89) 0.53 (0.32-0.82) 
Evaluation prior to an operation, n=316 0.52 (0.23-1.18) 0.54 (0.26-1.12) 
Evaluation of arrhythmia, n=869 0.41 (0.25-0.65) 0.59 (0.45-0.77) 
Evaluation after MI, n=256 0.29 (0.13-0.65) 0.53 (0.27-1.05) 
Evaluation of work capacity, n=897 0.41 (0.17-0.99) 0.68 (0.47-0.98) 
   
Patients reaching different level of exertion**   
Maximal, n=3040 0.49 (0.38-0.64) 0.64 (0.53-0.78) 
Almost Maximal, n=736 0.43 (0.26-0.71) 0.36 (0.23-0.58) 
*99% statins,**Assessed by the supervising physician after termination of the test. 
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Association between CRF and HRR and CA 
Similarly, both CRF and HRR associated with the risk of CA in univariate analyses and after 
adjusting for LVEF (univariate analysis: HRCRF 0.54, 95% CI 0.45-0.66, p=3.3e
-10 and HRHRR 0.66, 
95% CI 0.57-0.78, p=2.9e-7 and LVEF adjusted HRCRF 0.61, 95% CI 0.49-0.76, p=1.3e
-5 and HRHRR 
0.71, 95% CI 0.59-0.86, p=2.7e-4). All three factors persisted as significant also in the same model 
(HRCRF 0.66, 95% CI 0.52-0.82, p=2.8e
-4, HRHRR 0.78, 95% CI 0.64-0.95, p=0.013 and HRLVEF 
0.62, 95% CI 0.52-0.74, p=1.3e-7). 
 
 
DISCUSSION 
 
The results of this large prospective follow-up study of patients undergoing clinical exercise testing 
show that CRF and HRR are significant predictors of SCD regardless of LVEF in a contemporary 
patient population. Furthermore, both CRF and HRR associate with the risk of SCD among patients 
with normal or slightly reduced LVEF (>35%). 
Our results are in line with previous findings from other cohorts [13,14]. In the 
Kuopio Ischemic Heart Disease study of 2368 randomly selected middle aged Finnish men 
undergoing cycle ergometer testing in 1980s, one MET increase in CRF associated with an adjusted 
~22% relative decrease in SCD (17 years of follow-up). In the Aerobics Center Longitudinal Study 
of self referred subjects (n=55,456) undergoing treadmill testing between the years 1974 and 2002, 
the corresponding number was ~14% [14]. Our results are in line with an observed adjusted ~17% 
lower risk of SCD for one MET increase (extrapolated from the linear risk estimate). We also 
replicate the seminal results of Jouven et al. showing that among 5713 men undergoing exercise 
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testing between 1967 and 1972, reduced HRR predicted sudden death due to MI during a 23-year 
follow-up [4]. 
Adding to the findings of previous studies, we observed that the association between 
CRF and HRR with SCD is also independent of LVEF, which is currently the cornerstone in 
guiding ICD-therapy for the primary prevention of SCD [1,3]. Furthermore, the association is 
significant in a population with LVEF >35%. These patients are not generally eligible for ICD 
implantation for primary prevention of SCD despite the fact that the majority of SCDs occur among 
similar individuals of the general the population [1]. Similarly, in our study population 
approximately 80% of all SCDs occurred among subjects with LVEF >35%. Previously, the 
combination of reduced CRF and HRR has been shown to predict cardiovascular death and 
hospitalization due to congestive heart failure despite LVEF [18]. HRR has been also shown to 
associate with mortality independently of angiographic severity of CAD which is the underlying 
condition in most SCD cases and a significant contributor to LVEF reduction in the post-MI 
setting[19]. Similarly, HRR has been associated directly with mortality regardless of LVEF 
measured by stress echocardiography [20].  
According to previous studies, the relative risk of SCD seems to be higher when 
approaching lower levels of CRF or HRR (i.e. possible deviation from linearity)[4,13,14]. These 
trends seem very similar to the risk functions previously observed in regards to overall and 
cardiovascular mortality [12,20] and are also in line with our results. We also observed that the risk 
associated with poor HRR might be even stronger when measured after the exercise test is 
terminated before reaching absolute maximal exertion. This finding indicating a higher risk 
associated with poor HRR if present already in submaximal exertion is plausible but may also be a 
false positive given the number of interactions tested. Similarly, the association between HRR and 
SCD seemed stronger among women, but given the low number of SCDs among women (n=17) the 
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observation should be interpreted with caution. There are no prior studies that could validate this 
observation. 
The exact mechanisms by which CRF and HRR affect the risk of SCD are beyond the 
scope of this epidemiological study. However, previous evidence suggests that aside corresponding 
with favorable overall cardiovascular risk profile, good CRF is associated with a better cardiac 
autonomic function, which in turn may reduce the risk of fatal ventricular arrhythmias[13,16]. 
Similarly, HRR is considered a good indicator of parasympathetic function [15] even regardless of 
angiographic verified coronary artery status[19]. Considering this, it is plausible that, in the event of 
possible predisposing event such as an ischemic attack, both good CRF and HRR can provide 
protection from fatal arrhythmias. 
The other novelty of our study is the replication of the main findings [4,13,14] in a 
contemporary patient population subjected to most medical therapies currently available for 
reducing the risk of SCD (including beta-blockers, ACE inhibitors or ARBs and by statins)[3]. 
Previous studies have been conducted among patients treated almost entirely before the era of 
widespread use of these medications with populations undergoing exercise tests from the end of 
1960s to the end of the last millennia [4,13,14].  
CRF and HRR are also strong predictors of overall mortality [5,12,21]. This means 
that the prognostic utility of CRF and HRR might be compromised when considering interventions 
targeted specifically to reduce overall mortality by preventing SCD given the high risk of 
competing events that are not modifiable by any specific therapies aimed to reduce the risk of SCD. 
For this reason, other factors should also be considered in overall risk assessment. In the present 
study population, age, dementia due to any neurodegenerative disease and cancer all associated with 
the risk of dying due to other causes but not with the risk of SCD. It is plausible that CRF and HRR 
might be useful in guiding primary prevention of SCD among patients who have good functional 
status but not significantly burdened by other comorbidities. 
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Limitations 
The foremost limitation of the present study is that instead of measuring LVEF systematically at the 
time of the exercise tests, the LVEF information was measured only in patients with a clear clinical 
indication (71.4% of the population) and the information was extracted from patient records 
retrospectively. Despite the fact that patients with or without measured LVEF had substantially 
different risk profiles, associations between SCD and CRF and HRR seemed similar in both groups.  
The strengths of the present study include a large sample size resulting in reliable and 
consistent results as well as excellent coverage for the follow-up (no drop-outs). Due to Finnish 
legislature and centralized registry for recording causes of death we were able to determine the 
mode of death in all cases (sudden or not). For all patients who died, a full disclosure review of the 
death certificate was performed and in all cases with un-witnessed death or if the death was 
otherwise unexpected despite underlying conditions, the cause of death was determined by a 
medicolegal autopsy. The results were also confirmed using a secondary endpoint of all cardiac 
arrests (SCD combined with cardiac arrests leading to successful resuscitation). 
In conclusion, among subjects undergoing clinical exercise testing, CRF and HRR are 
significant predictors of SCD independently of LVEF. CRF and HRR are also significant 
prognostic factors for SCD among patients with only slightly reduced or normal LVEF. Further 
prospective trials are needed to verify the actual clinical value of CRF and HRR when considering 
primary prevention of SCD. 
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FIGURES 
 
Figure 1. Cardiorespiratory fitness and heart rate recovery distributions in the FINCAVAS study population 
of 3776 patients undergoing exercise testing for clinical indications  
 
Figure 2. The association curve for the sudden cardiac death risk by cardiorespiratory fitness and heart rate 
recovery in the follow-up of the prospective FINCAVAS study population of 3776 patients undergoing 
clinical exercise testing for clinical indications. The risk level is standardized to mean values for both 
exposure variables (7.7 METs and 25bpm/minute).  
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Cardiorespiratory fitness and heart rate recovery predict sudden cardiac death independent 
of left ventricular ejection fraction – The FINCAVAS Study 
 
Hernesniemi et al. 
 
 
 
 
 
SUPPLEMENTARY METHODS 
 
 
Indications for the exercise test 
 
Indications for the test were suspicion of CAD (43%), evaluation of work capacity (24%), 
arrhythmias (25%), adequacy of CAD drug therapy (13%) and evaluation prior to an invasive 
procedure (9%) or after myocardial infarction (MI) (7.6%). Some patients had more than one 
indication. 
 
Reasons for termination of the test and evaluation of achieved work level 
 
The reasons for termination of the test were chest pain (6%), dyspnoea (12%), fatigue (64%), ECG 
changes (1%), blood pressure changes (1%) or other reasons (10%). The objective exercise level as 
defined by the supervising physician was maximal in 81% or almost maximal in 19% of the tests. 
The achieved work level (classified as maximal, almost maximal, reasonable or small) was assessed 
by the supervising physician using patient’s reported level of exhaustion by the Borg’s scale and 
clinical judgement of the reasons for termination and perceived patient performance. 
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SUPPLEMENTARY TABLES 
 
Supplementary Table 1. The distribution of baseline demographics between patients who 
were alive or had died some other form of death and patients who died a sudden cardiac 
death during the follow-up of the FINCAVAS cohort. 
Status at the end of follow-up: Alive (n=3242) SCD (n=98) Other Death (n=436) 
Age 54.2 (12.8) 60.0 (11.1) 65.9 (10.3) 
Body-Mass Index 27.4 (4.6) 29.2 (5.1) 27.9 (4.4) 
Men (%) 58.9% 81.6% 67.9% 
Smoker 21.7% 27.6% 24.3% 
Previous MI 22.6% 64.3% 45.6% 
Previous Stroke 4.1% 10.2% 17.9% 
Diabetes 12.3% 29.6% 26.4% 
Cancer (any) 6.6% 13.3% 38.8% 
Heart Failure 4.0% 19.4% 20.6% 
Pulmonary Disease* 9.5% 20.4% 17.4% 
Peripheral Artery Disease 1.7% 8.2% 10.6% 
Atrial Fibrillation 14.8% 31.6% 24.3% 
Dementia 0.1% 1.0% 6.7% 
Use of Medications:    
ACEI/ARB 32.1% 66.3% 48.6% 
Beta blockers 51.9% 77.6% 71.6% 
Diuretics 16.5% 42.9% 35.1% 
Digoxin 2.2% 14.3% 6.7% 
Lipid Lowering Agent** 37.4% 52.0% 46.8% 
Serum Creatinine, umol/L 82 (60) 113 (132) 113 (121) 
Cardiorespiratory fitness 
(METs) 
8.1 (2.8) 5.9 (2.3) 5.8 (2.6) 
Heart Rate Recovery  25.8 (11.2) 18.4 (10.5) 18.4 (12.6) 
Max. Heart Rate (bpm) 150 (26) 130 (29) 126 (27) 
Max. Blood Pressure (mmHg) 197 (28) 182 (34) 183 (30) 
Sig. ST-depression*** 51.2% 37.9% 40.5% 
LVEF ≤35%**** 3.1% (n=70) 18.7% (n=14) 8.6% (n=29) 
*Chronic Obstructive Pulmonary Disease or Asthma 
 
**99.4% statins and 0.6% other 
***At least 0.1mV ST-segment depression during or after the exercise 
****Data available in 71% of the population. 
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Supplementary Table 2. Replication of main results without imputed data. Missing data for HRR 
n=138 (3.7%), serum creatinine n=128 (3.4%), blood pressure values n=5 (0.01%), QT and QTc 
interval n=173 (4.6%), QRS interval n=121 (3.2%) of the participants of the FINCAVAS study. 
 
*As in Table 2 of the main article, model adjusted with sex, history of myocardial infarction, 
prevalent pulmonary disease, atrial fibrillation, serum creatinine, LVEF and CRF/HRR).  
Abbreviations: HRR, Heart rate reduction; LVEF, left ventricular ejection fraction; CRF, 
Cardiorespiratory Fitness. 
 
 
 
  
 Hazard Ratio (95% Confidence Interval) 
HRR (univariate) n=3638 0.58 (0.49-0.68) 
HRR (adjusted with LVEF), n=2436 0.56 (0.43-0.72) 
HRR (adjusted with LVEF and CRF), n=2601 0.64 (0.51-0.81) 
HRR (full model without LVEF)*, n=3521 0.71 (0.57-0.89) 
HRR (full model)*, n=2522 0.72 (0.56-0.92) 
  
  
CRF (adjusted with LVEF and HRR) n=2601 0.61 (0.46-0.80) 
CRF (full model without LVEF)*, n=3521 0.65 (0.50-0.84) 
CRF (full model)*,  n=2522 0.69 (0.51-0.92) 
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Supplementary Table 3. The association between baseline risk factors (comorbidities and patient 
characteristics and medications) and sudden cardiac death in the FINCAVAS study population 
(n=3776). Information of left ventricular ejection fraction (LVEF) was available in 71.4% (n=2697) 
of the study population. 
 Hazard ratio (95% Confidence Interval) 
 Multivariable Multivariable with LVEF 
Sex (Male) 2.11 (1.23-3.64) 1.90 (1.01-3.56) 
Previous MI 3.64 (2.28-5.81)  3.43 (1.99-5.94) 
Pulmonary Disease† 1.69 (1.02-2.79) 1.75 (0.98-3.13) 
Atrial Fibrillation 1.64 (1.02-2.63) 1.67 (0.97-2.86) 
Serum Creatinine 1.11 (1.00-1.24) 1.10 (0.96-1.23) 
ACEI/ARB 1.98 (1.21-3.06) 2.32 (1.33-4.07) 
Beta blockers 0.85 (0.50-1.43) 0.66 (0.36-1.20) 
Diuretics 1.52 (0.96-2.41) 1.55 (0.92-2.62) 
Digoxin 2.05 (1.09-3.86) 1.34 (0.63-2.88) 
Lipid Lowering Agent 0.93 (0.60-1.45) 1.13 (0.67-1.88) 
Cardiorespiratory fitness  0.70 (0.53-0.91) 0.74 (0.55-1.00) 
Heart Rate Recovery  0.79 (0.64-0.99) 0.78 (0.61-1.01) 
QTc-interval - 1.23 (1.01-1.50) 
QRS duration 1.19 (1.02-1.41) - 
LVEF NA - 
LVEF ≤35%§ NA 2.45 (1.28-4.71) 
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Supplementary Table 4. The association between baseline demographics and mortality due to 
causes other than sudden cardiac death in the FINCAVAS study population. Risk estimates for only 
statistically significant or borderline significant (p<0.1) variables in the multivariable analyses are 
reported. Significant risk factors were selected to the model by a backward elimination algorithm. 
 
*Hazard ratio estimates correspond to a one standard deviation increase in exposure 
variables for continuous risk factors except for age for which the hazard estimate correspond 
to a one year increase. 
**Chronic Obstructive Pulmonary Disease or Asthma 
***At least 0.1mV ST-segment depression during or after the exercise. 
 
  
 Hazard ratio (95% Confidence Interval)* 
 Univariate Multivariable 
Age 1.09 (1.08-1.90) 1.05 (1.03-1.06) 
Body-Mass Index 1.02 (1.00-1.04) - 
Men (%) 1.37 (1.12-1.68) 1.27 (1.01-1.58) 
Smoker 1.04 (0.84-1.30) 1.39 (1.10-1.75) 
Previous MI 2.36 (1.95-2.85) 1.48 (1.20-1.81) 
Previous Stroke 3.76 (2.94-4.80) 1.45 (1.11-1.89) 
Diabetes 2.24 (1.81-2.77) - 
Cancer (any) 6.79 (5.60-8.23) 4.37 (3.56-5.35) 
Heart Failure 4.82 (3.81-6.08) 1.96 (1.52-2.54) 
Pulmonary Disease** 1.82 (1.42-2.36) - 
Peripheral Artery Disease 4.86 (3.58-6.59) 1.62 (1.17-2.24) 
Atrial Fibrillation 1.74 (1.40-2.16) - 
Dementia due to any cause 9.03 (6.19-13.16) 3.42 (2.29-5.12) 
Serum Creatinine, umol/L 1.15 (1.11-1.20) 1.17 (1.11-1.23) 
Cardiorespiratory fitness (METs) 0.46 (0.41-0.52) 0.74 (0.65-0.85) 
Heart Rate Recovery  0.58 (0.53-0.62) 0.84 (0.75-0.94) 
Max. Heart Rate (bpm) 0.49 (0.45-0.54) - 
Max. Blood Pressure (mmHg) 0.65 (0.59-0.71) 0.90 (0.81-1.00) 
Sig. ST-depression*** 0.66 (0.55-0.80) - 
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Supplementary Table 5. The unadjusted hazard ratios associated with different combinations of 
CRF and HRR levels. The population is stratified to equal size tertiles according to CRF and HRR 
values and the risk associated with different number of risk points are presented. Each subject is 
assigned risk points by their level of risk according to CRF and HRR tertile stratification. The 
highest tertile for both yields no risk points whereas position in the middle tertile equals one risk 
point and position in the lowest risk tertile two risk points. 
 
 Hazard ratio (95% Confidence Interval) 
Reference (zero risk points) 1.00 
One risk point 1.92 (0.61-6.04) 
Two risk points 4.00 (1.39-11.45) 
Three risk points 4.61 (1.58-13.50) 
Four risk points 10.22 (3.65-28.64) 
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Supplemental Figure 1. The association curve for the sudden cardiac death risk by cardiorespiratory 
fitness and heart rate recovery after adjusting for left ventricular ejection fraction. The risk level is 
standardized to mean values for both exposure variables (7.7 METs and 24.7bpm/minute). 
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